A systematic review of 23 studies comprising 535 patients comparing HER2 scores 0 and 1+ showed that HER2-low breast cancer is more common (67.5%) in the hormone receptor (HR)-positive compared with the HR-negative group (48.6%). This evidence concerns the gene NR4A1 and breast cancer.